Daiichi's U.S. comPlexx
Buying Plexxikon jump starts Daiichi Sankyo's U.S. commercial presence in cancer
Although Roche has worldwide rights to Plexxikon Inc.'s PLX4032, the opportunity to jump start a U.S. commercial presence in cancer on the back of co-promotion rights is leading Daiichi Sankyo Co. Ltd. to acquire the biotech for $805 million up front.
Interim Phase III data for PLX4032 were reported in January, and Roche plans to submit marketing applications in the U.S. and Europe this year.
The deal also provides the Japanese pharma with two more clinical candidates and Plexxikon's scafforld-based discovery engine.
Glenn Gormley, Daiichi Sankyo's CSO and co-head of R&D, told BioCentury the company decided about a year ago